RP-HPLC法同时测定人血清中拉莫三嗪、苯巴比妥、奥卡西平及其活性代谢物单羟基卡马西平的浓度
x
请在关注微信后,向客服人员索取文件
篇名: | RP-HPLC法同时测定人血清中拉莫三嗪、苯巴比妥、奥卡西平及其活性代谢物单羟基卡马西平的浓度 |
TITLE: | |
摘要: | 目的:建立同时测定人血清中拉莫三嗪(LTG)、苯巴比妥(PBB)、奥卡西平(OXC)及其活性代谢物单羟基卡马西平(MHD)浓度的方法。方法:血清采用二氯甲烷液-液萃取法处理后以反相高效液相色谱(RP-HPLC)法进样测定,色谱柱为Kromasil 100-C18,流动相为水相(由0.5%三氟乙酸与14 mmol/L甲酸铵溶液按2 ∶ 1体积比混合)-乙腈(76 ∶ 24,V/V),流速为1.0 ml/min,柱温为常温,紫外检测波长为215 nm。结果:MHD、LTG、PBB和OXC血药浓度分别在0.40~80.35、0.41~81.10、0.45~90.00、0.39~78.80 μg/ml范围内线性关系良好(r均>0.999 3,n=7);提取回收率为54.09%~83.78%,方法回收率为93.83%~113.25%,各待测组分的日内、日间RSD均≤13.51%。其他常用药物不影响待测组分的测定。结论:本方法准确、灵敏、特异性强、测定时间短,可满足临床常规治疗药物监测的需要。 |
ABSTRACT: | OBJECTIVE: To establish a method for simultaneous determination of lamotrigine (LTG), Phenobarbital (PBB), oxcarbazepine (OXC) and its active metabolite monohydroxycarbazepine (MHD) in human serum. METHODS: Serum samples were extracted with dichloromethane by liquid-liquid extraction, and then determined by RP-HPLC. Kromasil 100-C18 column was used with mobile phase consisted of acetonitrile (0.5% TFA and 14 mmol/L formic acid amine solution, 2 ∶ 1,V/V)-acetonitrile (76 ∶ 24, V/V) at flow rate of 1.0 ml/min. The column temperature was room temperature, and detection wavelength was set at 215 nm. RESULTS: The liner range of MHD, LTG, PBB and OXC were 0.40-80.35, 0.41-81.10, 0.45-90.00 and 0.39-78.80 μg/ml, respectively (all r>0.999 3, n=7). The extraction recovery was 54.09%-83.78%, and method recovery was 93.83%-113.25%. Both inter-day and intra-day RSDs were less than 13.51%. Other commonly used drugs didn’t affect the determination of component to be measured. CONCLUSIONS: The method is accurate, sensitive and specific, and spend less time. It can meet the demand of clinical drug monitoring. |
期刊: | 2016年第27卷第11期 |
作者: | 沈芊,王彦改,曾红,王雪梅,闫素英 |
AUTHORS: | SHEN Qian,WANG Yangai,ZENG Hong,WANG Xuemei,YAN Suying |
关键字: | 拉莫三嗪;奥卡西平;苯巴比妥;单羟基卡马西平;血药浓度;反相高效液相色谱法 |
KEYWORDS: | Lamotrigine; Oxcarbazepine; Phenobarbital; Monohydroxycarbazepine; Drug concentration; RP-HPLC |
阅读数: | 314 次 |
本月下载数: | 2 次 |
* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!